Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418083 | 1.00 | CETP (0.47) | CETPCYP1A1CYP1B1TBXA2RPTGDR | |
| SCHEMBL6418148 | 0.85 | LY96 (0.38) | CETPCYP1A1CYP1B1KDM1AHDAC8 | |
| SCHEMBL6418150 | 0.85 | LY96 (0.38) | CETPCYP1A1CYP1B1KDM1AHDAC8 | |
| SCHEMBL6418675 | 0.83 | CETP (0.49) | CETPTBXA2RPTGDRPTGDR2SLC2A1 | |
| SCHEMBL6794217 | 0.81 | CETP (0.48) | CETPTBXA2RPTGDRPTGDR2SLC2A1 | |
| SCHEMBL6419019 | 0.80 | RXRA (0.49) | CETPTBXA2RPTGDRPTGDR2SLC2A1 | |
| SCHEMBL7370771 | 0.77 | PTGER4 (0.43) | CYP1A1CYP1B1HDAC8MAPT | |
| SCHEMBL7370769 | 0.77 | PTGER4 (0.43) | CYP1A1CYP1B1HDAC8MAPT | |
| SCHEMBL14304617 | 0.73 | KDM4E (0.46) | HDAC8MAPT | |
| SCHEMBL2056134 | 0.71 | HDAC3 (0.49) | CETPTBXA2RPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1017387-A4 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030216377-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030087894-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| US-20020128257-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1017387-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999015170-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | CETP 3898/4885CYP1A1 3759/4885CYP1B1 2881/4885 |
| US-20030087894-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | CETP 3898/4885CYP1A1 3759/4885CYP1B1 2881/4885 |
| US-20020128257-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | CETP 3898/4885CYP1A1 3759/4885CYP1B1 2881/4885 |
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | CETP 3466/4885CYP1A1 3096/4885CYP1B1 2371/4885 |
| US-20030216377-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | CETP 3898/4885CYP1A1 3759/4885CYP1B1 2881/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | CETP 3898/4885CYP1A1 3759/4885CYP1B1 2881/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | CETP 3466/4885CYP1A1 3096/4885CYP1B1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.